Pharmaceutical

Catabasis

$2.66
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.05 (+1.92%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Catabasis and other stocks, options, and ETFs commission-free!

About CATB

Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA. The listed name for CATB is Catabasis Pharmaceuticals, Inc. Common Stock.

CEO
Jill C. Milne
Employees
27
Headquarters
Boston, Massachusetts
Founded
2008
Market Cap
48.31M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.08M
High Today
$2.67
Low Today
$2.53
Open Price
$2.63
Volume
478.83K
52 Week High
$8.59
52 Week Low
$1.25

Collections

CATB Earnings

-$0.64
-$0.43
-$0.21
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 9, After Hours

You May Also Like

RCA
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure